title: Effect of Danzhijiangtang capsule on monocyte chemoattractant protein-1 mRNA expression in newly diagnosed diabetes subclinical vascular lesions.
abstract: OBJECTIVE
  To investigate the effect of Danzhijiangtang capsule (DJC) on monocyte chemoattractant protein-1 (MCP-1) mRNA expression in newly diagnosed type 2 diabetes mellitus (T2DM) subclinical vascular lesions.
  
  
  METHODS
  Sixty-two patients with newly diagnosed T2DM subclinical vascular lesions were randomly divided into a control group and treatment group of 31 cases each. Oral antidiabetic therapy with routine western medicine was conducted in both groups, and the treatment group was additionally treated with DJCs. The treatment course for both groups was 12 wk. Before and after treatment, the total efficiency and traditional Chinese medicine (TCM) syndrome score were calculated. The fasting plasma glucose (FPG), 2-h plasma glucose (2hPG), fasting insulin (FINS), insulin resistance index (IRI), hemoglobin (Hb)A1c, blood lipids, and hemorheology indices were determined. In addition, the levels of vascular endothelial growth factors including thrombomodulin (TM), von Willebrand factor (vWF), P-selectin and MCP-1 mRNA were determined.
  
  
  RESULTS
  After 12 wk of treatment, the TCM syndrome score was significantly decreased compared to before treatment in both groups. After treatment, FPG, 2hPG, HbA1c, FINS, IRI, total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein, whole blood low shear specific viscosity, plasma specific viscosity, TM, vWF, P-selectin and MCP-1 mRNA were significantly improved compared to before treatment in both groups. After treatment, the total efficiency and TCM syndrome score in the treatment group were better than in the control group. FINS, IRI, whole blood high shear specific viscosity, plasma specific viscosity, TM, vWF, P-selectin and MCP-1 mRNA level in the treatment group were significantly reduced after treatment compared with control group.
  
  
  CONCLUSIONS
  DJCs are efficacious in supplementing qi, nourishing yin and invigorating blood circulation, and upregulate MCP-1 mRNA expression in patients with T2DM subclinical vascular lesions.
authors.affiliation: Department of Endocrinology, the First Affiliated Hospital of Anhui College of Traditional Chinese Medicine, Hefei 230031, Anhui Province, China. fangzhaohui@medmail.com
authors.forename: Zhao-Hui
authors.initials: ZH
authors.lastname: Fang
authors.forename: Yan
authors.initials: Y
authors.lastname: Liu
authors.forename: Tao-Tao
authors.initials: TT
authors.lastname: Bao
authors.forename: Ying-Qun
authors.initials: YQ
authors.lastname: Ni
authors.forename: Jian
authors.initials: J
authors.lastname: Liu
authors.forename: Guo-Bin
authors.initials: GB
authors.lastname: Shi
authors.forename: Ji-Ping
authors.initials: JP
authors.lastname: Wu
authors.forename: Jun-Ping
authors.initials: JP
authors.lastname: Yang
authors.forename: Hong
authors.initials: H
authors.lastname: Zhang
mesh_terms: D000284:Administration, Oral; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002214:Capsules; D018932:Chemokine CCL2 / Q000235:genetics*; D016009:Chi-Square Distribution; D002681:China; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D003925:Diabetic Angiopathies / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D019007:P-Selectin / Q000097:blood; D012333:RNA, Messenger / Q000097:blood*; D018180:Thrombomodulin / Q000097:blood; D013997:Time Factors; D016896:Treatment Outcome; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D002214:Capsules; D018932:Chemokine CCL2; D004365:Drugs, Chinese Herbal; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D019007:P-Selectin; D012333:RNA, Messenger; D018180:Thrombomodulin; D014841:von Willebrand Factor; C111835:CCL2 protein, human; C546937:SELP protein, human; C546931:THBD protein, human; C517652:hemoglobin A1c protein, human
keywords: Danzhijiangtang capsule; Monocyte chemoattractant protein-1; Subclinical vascular lesions; Type 2 diabetes mellitus